Using HSV-TK/GCV suicide gene therapy to inhibit lens epithelial cell proliferation for treatment of posterior capsular opacification by Jiang, Yong-Xiang et al.
Using HSV-TK/GCV suicide gene therapy to inhibit lens epithelial
cell proliferation for treatment of posterior capsular opacification
Yong-Xiang Jiang,1 Yi Lu,1 Tian-Jing Liu,2 Jin Yang,1 Yan Chen,1 Yan-Wen Fang1
1Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China; 2Genetic Engineering Group, Institute
of Biochemistry and Cell Biology, Chinese Academy of Science, Shanghai, China
Purpose:  To  establish  a  novel,  targeted  lentivirus-based  HSV-tk  (herpes  simplex  virus  thymidine  kinase)/GCV
(ganciclovir)  gene  therapy  system  to  inhibit  lens  epithelial  cell  proliferation  for  treatment  of  posterior  capsular
opacification (PCO) after cataract surgery.
Methods: An enhanced Cre recombinase (Cre/loxP) system with a lentiviral vector expressing Cre under the control of
the lens-specific promoter LEP503 (Lenti-LEP503-HSVtk-Cre [LTKCRE]) was constructed, as well as another lentiviral
vector containing a switching unit. The latter vector contains a stuffer sequence encoding EGFP (Lenti-hPGK-Loxp-
EGFP-pA-Loxp-HSVtk [PGFPTK]) with a functional polyadenylation signal between two loxP sites, followed by the
herpes simplex virus thymidine kinase (HSV-tk) gene, both under the control of the human posphoglycerate kinase
(hPGK) promoter. Expression of the downstream gene (HSV-tk) is activated by co-expression of Cre. Human lens epithelial
cells (HLECs) or retinal pigmental epithelial cells (RPECs) were co-infected with LTKCRE and PGFPTK. The inhibitory
effects on HLECs and RPECs infected by the enhanced specific lentiviral vector combination at the concentration of 20
µg/ml GCV were assayed and compared.
Results: The specific gene expression of Cre and HSV-tk in HLECs is activated by the LEP503 promoter. LTKCRE and
PGFPTK co-infected HLECs, but not RPECs, expressed high levels of the HSV-tk protein. After 96 h of GCV treatment,
the percentage of apoptotic HLECs infected by the enhanced specific lentiviral vector combination was 87.23%, whereas
that of apoptotic RPECs was only 10.12%. Electron microscopy showed that GCV induced apoptosis and necrosis of the
infected HLECs.
Conclusions: The enhanced specific lentiviral vector combination selectively and effectively expressed HSV-tk in HLECs.
A concentration of 20 µg/ml, GCV is effective against the proliferation of HLECs in vitro. This cell-type-specific gene
therapy using a Cre/loxP lentivirus system may be a feasible treatment strategy to prevent PCO.
Posterior  capsular  opacification  (PCO)  caused  by
proliferation of residual epithelial cells over the lens equator
and onto the posterior lens capsule [1] is the leading cause of
visual impairment and blindness after cataract surgery [2-4].
There are currently no effective means by which to eradicate
the residual lens epithelial cells during the operation [5,6]. In
spite of improvements in the basic research on development
of cataracts, surgical techniques, and the material or the design
of the intraocular lens, the incidence of PCO is still 8~34.3%
in  adults,  and  nearly  100%  in  children  [7-10].  One  new
promising approach for treatment of PCO is a gene therapy
system uses a so-called suicide gene, the herpes simplex virus
type 1 thymidine kinase (HSV-tk) gene, and the anti-herpes
nucleoside analog drug, ganciclovir (GCV) [11-13]. In this
system,  GCV  is  phosphorylated  by  HSV-tk  into  a
deoxynucleotide analog that becomes incorporated into DNA
during strand replacement in proliferating cells, where it acts
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as a chain terminator of DNA synthesis and kills the dividing
cells [14-16].
However, the standard HSV-tk/GCV system is driven by
a constitutive promoter [11,12], and was shown to not only
cause the death of the lens epithelial cells, but also of the
corneal endothelial cells and the iris pigmental epithelial cells
[11]. This cytotoxic side effect is the main obstacle for further
clinical application of this system. However, the use of a lens-
specific promoter would greatly benefit the application of this
system for treatment of PCO. LEP503 (lens epithelium gene
product 503), which is a highly conserved gene involved in
lens  epithelial  cell  differentiation  in  different  vertebrate
species, is localized in the epithelial cells along the entire
anterior surface of the lens. LEP503 may be an important lens
epithelial cell gene involved in the processes of epithelial cell
differentiation  [17].  The  expression  of  LEP503  is  highly
restricted to lens epithelial cells in vivo, and 2.5-kb flanking
sequence-directed  high-level  promoter  activity  in  lens
epithelial cells,but not in other cell types [18]. Malecaze et al.
[19] found that LEP503,MIP (major intrinsic protein), and
Filensin promoters induced strong lens-specific expression of
a reporter gene in human lens cells. The efficacy of LEP503
promoters for a reporter gene expression is restricted to the
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291residual  lens  cells  post-PCO.  We  have  found  that  human
cytomegalovirus  (CMV)  promoter  driven  HSV-TK  can
inhibited the HLEC proliferation, though this system has no
cell specification [20,21]. To avoid the toxic effects of the
constitutive promoter on the surrounding normal cells, we
constructed the HSV-tk/GCV vector with the lens-specific
promoter LEP503 (Lenti-LEP503-EGFP-HSVtk [LGFPTK])
and found that it can specifically express the HSV-tk protein
in lens epithelial cells. However, the promoter inserted in this
vector cannot provide high levels of expression. Indeed, the
transduction  efficiency  of  this  vector  was  only  17.32%.
Because the expression of HSV-tk induced by the lens-specific
promoter LEP503 was lower than that of the CMV promoter,
we  reasoned  that  it  would  not  effectively  inhibit  the
proliferation of lens epithelial cells.
It was recently reported that gene therapy using the Cre/
loxP system greatly enhances the expression of the HSV-tk
gene [15,22-24], especially that transduced by adenoviruses
under the control of tissue-specific promoters such as the
carcinoembryonic antigen (CEA) promoter and thyroglobulin
promoter [24,25]. In these studies, the sensitivity of tumor
cells to GCV was increased up to 5 to 10-fold compared with
sensitivity in the presence of the promoter alone [26].
In the present study, to enhance the expression of the lens-
specific promoter LEP503, we employed the HSV-tk/Cre/
loxP system for gene therapy, targeting human lens epithelial
cells  (HLECs).  Cre-loxP  system-mediated  lentiviruses,
bearing  an  ON/OFF  switching  unit  for  activation  by  Cre
recombinase, were used. We constructed an enhanced specific
lentiviral vector combining two vectors: one is a regulatory
vector (Lenti-LEP503-HSVtk-Cre [LTKCRE]) that expresses
the Cre recombinase gene under the control of the LEP503
promoter,  while  the  other  is  a  target  vector(Lenti-hPGK-
Loxp-EGFP-pA-Loxp-HSVtk  [PGFPTK]).  The  switching
unit  in  the  lentiviral  vector  contains  a  stuffer  sequence
encoding enhanced green fluorescent protein (EGFP) with a
functional  polyA  sequence  between  the  strong  human
posphoglycerate kinase (hPGK) promoter and the inserted
HSV-tk fragment, thereby inducing EGFP gene expression
without HSV-tk expression. A pair of loxP sites flanking the
stuffer sequence allows its excision by the Cre recombinase,
leading  to  expression  of  the  HSV-tk  sequence  instead  of
EGFP.
Thus,  we  used  the  regulatory  vector  (LTKCRE)  to
express  the  HSV-tk  protein  and  Cre  recombinase  after
infection of HLECs by the two lentiviral vectors. The induced
Cre recombinase should excise the functional polyA sequence
interposed between the two loxP sites in the target vector
(PGFPTK). Consequently, HSV-tk gene expression would be
driven by the stronger hPGK promoter after activation by Cre
recombinase. The amount of HSV-tk expressed by the Cre/
loxP system-mediated lentiviruses should be greater than that
expressed by the lentiviruses driven only by lens-specific
promoter LEP503 (Figure 1). We then evaluated the efficacy
of gene therapy against proliferation of HLECs using these
vectors with the Cre/loxP system and GCV treatment. Our
findings  provide  experimental  evidence  for  further
development of this potential therapy for clinical treatment of
PCO.
METHODS
Construction  of  the  enhanced  specific  lentiviral  vector
combination:  The  enhanced  specific  lentiviral  vector
combination  includes  two  lentiviral  vectors.  One  is  a
regulatory vector (LTKCRE), while the other is a target vector
(PGFPTK). Cre recombinase was cloned from the Lenti-Cre
Figure 1. The mechanism of the Cre/
loxP  system  combined  with  the  lens-
specific  promoter  LEP503  based  on
lentiviral vectors.
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292plasmid by PCR, and sub-cloned into a T vector, which was
double-digested by EcoRI and SalI enzymes. At the same
time, the LGFPTK plasmid (constructed in our laboratory,
unpublished  data)  was  also  digested  by  EcoRI  and  SalI
enzymes. The two digested sections were ligated together to
construct the regulatory vector LTKCRE. Loxp-polyA-Loxp
was artificially synthesized with a PmeI enzyme site at the 5′
end of the polyA, and was inserted into a T vector along with
EGFP,  which  had  PmeI  enzyme-digested  sites  at  both
terminal ends, resulting in the Loxp-EGFP-pA-Loxp vector.
The Loxp-EGFP-pA-Loxp vector and plasmid PRRL were
both double-digested by BamHI and SalI enzymes and then
directionally combined. IRES-HSVtk was cloned by PCR
with SalI restriction sites at both ends and inserted into the
SalI-digested construction vector to produce the target vector
PGFPTK.
Production  of  lentiviral  vectors:  Replication-defective
lentiviral particles pseudotyped with a VSV-G envelope were
produced by three plasmid transient transfections of 293T
cells, as previously described [20], with 20 μg of one of the
gene  transfer  constructs  (LTKCRE,  PGFPTK),  12  μg  of
psPAX2, and 5 μg of pMD2.G using a calcium phosphate
transfection  kit  (Gibco-BRL,  Gaithersburg,  MD).  The
transfection medium was replaced with fresh culture medium
after 14 to 16 h. The conditioned medium was collected after
another 24 h, cleared by low-speed centrifugation, and filtered
through 0.45-mm filters (Nalgene, Rochester, NY). The virus
was collected by ultracentrifugation for 90 min at 80,000× g
at 4 °C. The pellet was resuspended in 1 ml phosphate buffered
saline (PBS).
FACS and PCR analysis of the infection efficiency of the
lentiviral infection: To determine the infection efficiency of
the enhanced specific lentiviral vector combination (PGFPTK
and  LTKCRE),  EGFP  expression  was  visualized  by
fluorescence microscopy and analyzed by FACS. Because the
regulatory  vector  LTKCRE  does  not  express  EGFP,  we
detected the infection efficiency of LGFPTK. The HLEC line
(SRA 01/04, cell line transformed by large T antigen) and
retinal pigmental epithelial cells (RPECs, A PRE-19) were
obtained from the ATCC (Manassas, VA ) and cultured in
DMEM with 10% FBS. The HLECs and RPECs were plated
separately at 2×105 cells/well in 6-well plates for 24 h, and
then LGFPTK and PGFPTK at a multiplicity of infection
(MOI) of 20 were added. Polybrene (8 μg/ml) was added to
the two sets of cultures, and the infected HLECs and RPECs
were cultured for 72 h. EGFP expression in the HLEC group
was visualized by fluorescence microscopy and analyzed by
FACS.  The  primer  sequences  were  as  follows:  EGFP
(upstream 5′-cga gct gga cgg cga cgt aaa c-3′; downstream 5′-
gcg ctt ctc gtt ggg gtc ttt g-3′) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; upstream 5′-aac gag cgg ttc cga tgc
cct gag-3′; downstream 5′-tgt cgc ctt cac cgt tcc agt t-3′).
Cycling conditions for amplification were: 94 °C for 5 min;
28 cycles at 94 °C for 1 min, 58 °C for 1 min, and 72 °C for
1 min; and finally, 72 °C for 10 min. The expected length of
the  EGFP  PCR  products  was  597  bp.  Differences  in
expression were normalized to the GAPDH signal (590 bp).
Ten  microliters  from  each  RT–PCR  product  was
electropheresed on a 1.5% agarose gel containing 0.5 µg/ml
of ethidium bromide.
The expression of EGFP in HLECs and RPECs infected by
the  enhanced  specific  lentiviral  vector  combination:  To
analyze the expression of EGFP, the HLECs and RPECs were
plated separately at 2×105 cells/well in 6-well plates, and
LTKCRE (MOI=100), PGFPTK (MOI=20), or the enhanced
specific lentiviral vector combination (PGFPTK [MOI=20]
and LTKCRE [MOI=100]) were added. Polybrene (8 μg/ml)
was added to all cultures, and the infected HLECs and RPECs
were cultured for 72 h. EGFP expression in the HLEC group
and RPEC group were visualized by fluorescence microscopy
and analyzed by FACS.
Western blotting analysis: To analyze the protein expression
of  Cre,  EGFP,  and  HSV-tk  from  the  lentiviral  vectors,
1×106 HLECs were seeded in 25 mm2 cell culture flasks for
24 h and then LTKCRE (MOI=100), PGFPTK (MOI=20), or
the enhanced specific lentiviral vector combination (PGFPTK
[MOI=20] and LTKCRE [MOI=100]), was added. At 72 h
after the infection, the cells were boiled with 6× loading buffer
for 10 min, and the cell proteins (20 μg) were separated in
SDS–PAGE gels, followed by blotting onto polyvinylidene
difluoride  (PVDF)  membranes.  The  anti-β-actin  antibody
from  Santa  Cruz  Biotechnology  (1:5000,  Heidelberg,
Germany)  and  anti-Cre,  anti-EGFP,  and  anti-HSV-tk
antibodies from Sigma-Aldrich (1:2,000; St. Louis, MO) were
used to detect the lentivirally expressed Cre, EGFP, and HSV-
tk  proteins.  The  membranes  were  then  incubated  with  a
horseradish peroxidase-conjugated goat anti-mouse or anti-
rabbit secondary antibody (Amersham, Arlington Heights, IL)
and  visualized  using  a  chemiluminescence  system
(Amersham™ ECL).
Cytotoxicity of GCV: To evaluate the cytotoxicity of GCV
(InvivoGen, SanDiego, CA) treatment, apoptotic levels of
HLECs and RPECs were evaluated. HLECs and RPECs were
plated separately in 96-well plates at a density of 5×104 cells/
well and incubated for 24 h. Cells infected with Lenti-hPGK-
EGFP-HSVtk  (MOI=20),  LTKCRE  (MOI=100),  or  the
enhanced  specific  lentiviral  vector  combination  (PGFPTK
[MOI=20]  and  LTKCRE  [MOI=100])  served  as  the
therapeutic groups, and cells infected with Lenti-IRES-EGFP
(MOI=20) served as the control group. After 24 h, the four
groups  of  cells  were  treated  with  GCV  at  increasing
concentrations (0, 10, 20, 30, 40, and 50 μg/ml) and incubated
at 37 °C in 5% CO2 for 4 days. Each group was assayed in
triplicate for each concentration. Apoptosis of infected cells
after the 4-day incubation was evaluated quantitatively by
measuring  phosphatidylserine  externalization,  an  early
apoptosis-related event. This was performed by fluorescence
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293staining using the annexin V(blue)-PI staining kit (Roche,
Basel,  Switzerland)  as  per  the  manufacturer’s
recommendations.
To further evaluate the cytotoxicity of GCV treatment,
HLECs were plated in 96-well plates at a density of 5×104
cells/well and incubated for 24 h. Cells infected with Lenti-
hPGK-EGFP-HSVtk  (MOI=20),  LTKCRE  (MOI=100),  or
the  enhanced  specific  lentiviral  vector  combination
[(PGFPTK (MOI=20) and LTKCRE (MOI=100)] served as
therapeutic groups, and cells infected with Lenti-IRES-EGFP
(MOI=20) served as a control group. After 24 h, the four
groups were treated with GCV at increasing concentrations
(0, 10, 20, 30, 40, and 50 μg/ml) and incubated at 37 °C in 5%
CO2 for 1 to 4 days. Cell viability of the four groups was
determined using the Cell Counting kit-8 Cell Proliferation
Assay (Dojindo, Kumamoto, Japan) after 24 or 96 h. At each
time  point,  cells  were  assayed  in  triplicate  for  each
concentration.  The  cytotoxic  effect  was  indicated  as  the
percentage of surviving cells (ratio of surviving cells after
treatment and without treatment) using the following formula:
cell viability=(absorption of lenti-HSV-tk-EGFP−absorption
of  background)/(absorption  of  lenti-EGFP  absorption  of
background) × 100%. A p value of <0.05 was considered
statistically significant.
Electron  microscopy:  HLECs  (1×106/well,  6-well  plates)
infected  with  the  enhanced  specific  lentiviral  vector
combination  (PGFPTK  [MOI=20]  and  LTKCRE
[MOI=100]) served as a therapeutic group; HLECs infected
with Lenti-IRES-EGFP (MOI=20) served as a control group.
After treatment with GCV (20 μg/ml) for 96 h, cells were
collected with a cell scraper, followed by three 10-min washes
in PBS at room temperature. The cell pellet was fixed with
5% glutaraldehyde for at least 30 min, fixed in PBS containing
1% osmium tetroxide for 1 h, dehydrated in grading ethanol,
and  embedded  in  resin.  Sections  (100  nm  thick)  were
counterstained  with  uranyl  acetate  and  lead  citrate  and
examined  by  transmission  electron  microscopy  (H-7650;
Hitachi,  Tokyo,  Japan).  The  characteristic  morphologic
changes  of  infected  HLECs  were  recorded,  including
chromatin  condensation,  plasma  membrane  blebbing,  cell
shrinkage, and fragmentation into membrane bound bodies.
Statistical analysis: Treatments were examined and analyzed
statistically using the SPSS statistical package, version 11.0
(SPSS Inc., Chicago, IL) for Windows. Data are expressed as
mean±standard deviation of separate experiments. ANOVA
and t tests were performed to assess the statistical significance
between different groups. A p value of <0.05 was considered
statistically significant.
RESULTS
The LEP503 promoter drives EGFP expression specifically
but relative weakly in HLECs: In comparing HLECs at 3 days
post-infection by two lentiviral vectors (MOI=20), a stronger
fluorescent  signal  was  detected  after  PGFPTK  infection
(Figure 2A). However, a low level of EGFP expression was
detected  in  the  HLECs  infected  by  LGFPTK  under  a
fluorescence microscope (Figure 2B). FACS detections of
positive EGFP were 98.64% (Figure 2C) and 25.58% (Figure
2D) by PGFPTK and LGFPTK infection, respectively. This
demonstrated  that  the  constitutive  promoter  hPGK  was
stronger than the LEP503 promoter in HLECs. To detect the
specificity of the LEP503 promoter in HLECs, we analyzed
the expression of EGFP in HLECs and RPECs, which are both
important cells related to visual function in eye. RT–PCR
results showed that PGFPTK expressed well in both HLECs
and  RPECs.  However,  LGFPTK  was  only  expressed  in
HLECs, as there was no detectable EGFP in RPECs (Figure
2E). This result demonstrated that the LEP503 promoter can
specifically induce HSVtk-EGFP expression in HLECs with
lower efficiency than the constitutive promoter hPGK.
The enhanced specific lentiviral vector combination drives
high  HSVtk  protein  expression  in  HLECs:  The  enhanced
specific  lentiviral  vector  combination  was  composed  of
LTKCRE and PGFPTK. The mechanism of this expression
system is shown in Figure 1. LTKCRE specifically expressed
the HSV-tk protein and Cre recombinase in HLECs. PGFPTK
could express EGFP well, but not HSV-tk with the polyA
behind EGFP. When both of them were expressed in HLECs,
LEP503 specifically induced the Cre recombinase (LTKCRE)
to excise the functional polyA sequence interposed between
the two loxP sites in the target vector (PGFPTK). Then, HSV-
tk gene expression could be driven by the stronger hPGK
promoter after activation by the Cre recombinase. The HSV-
tk expressed by this vector combination was greater than that
expressed in the presence of the promoter alone (LTKCRE).
To estimate the transduction efficiency and specificity of the
lentiviral  vectors,  we  infected  HLECs  (Figure  3A-C)  and
RPECs (Figure 3D-F). The regulatory vector LTKCRE did
not  express  EGFP  (Figure  3A,D).  The  transduction
efficiencies of PGFPTK in HLECs and RPECs measured by
FACS  analysis  were  97.43%  and  92.15%,  respectively
(Figure  3B,E).  Meanwhile,  the  expression  of  EGFP  was
drastically  reduced  to  6.3%  by  this  enhanced  specific
lentiviral vector combination in HLECs (Figure 3C), and there
was no significant change in expression between the lentiviral
vector combination applied to RPECs (86.46%; Figure 3F)
and that from the infection of PGFPTK in RPECs (Figure 3E).
We analyzed the expressions of Cre, EGFP, and HSV-tk by
western  blot  analysis  (Figure  3G).  As  expected,  Cre  was
expressed only in the HLECs infected by LTKCRE and the
enhanced specific lentiviral vector combination. No EGFP
expression was observed in the HLECs infected by LTKCRE,
whereas EGFP expression in HLECs infected by PGFPTK
was stronger than infection by the enhanced specific lentiviral
vector  combination.  For  HSV-tk,  HLECs  infected  by  the
enhanced  specific  lentiviral  vector  combination  showed
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weak expression in the HLECs infected by PGFPTK.
Apoptosis of HLECs treated with GCV in different lentiviral
vector  groups:  The  cell  morphologic  changes  of  the
therapeutic  group  (the  enhanced  specific  lentiviral  vector
combination) and the control group (Lenti-IRES-EGFP) were
studied using transmission electron microscopy. Compared
with the normal shapes and sizes of the cells in the control
group  (Figure  4A),  the  typical  morphologic  changes  of
apoptosis were seen in the enhanced specific lentiviral vector
combination infected cells treated with 20 μg/ml GCV for 96
h (Figure 4B). The characteristics of apoptosis included cell
shrinkage, chromatin condensation, nuclear fragmentation,
and cytoplasm degradation. The nuclei were irregular and
bulbous; at the same time, necrosis was seen in a few cells of
the therapeutic group (Figure 4C). The cells were swollen with
a collapsed membrane, loss of structural integrity, and round
mitochondria.  Intracellular  contents  were  released,  which
indicated  a  typical  pattern  of  cell  necrosis.  The  electron
microscopy results showed that GCV at a concentration of
20 μg/ml can induce apoptosis and necrosis of cells infected
with the enhanced specific lentiviral vector combination.
Apoptotic levels of HLECs and RPECs were analyzed by
FACS 96 h after infection in different lentiviral vector groups
treated with GCV at the concentration of 20 µg/ml (Figure
4D). The percentage of apoptosis in the HLECs infected with
the enhanced specific lentiviral vector combination (PGFPTK
and LTKCRE) was 87.23%, and the percentage of apoptosis
in  the  positive  control  vector  (Lenti-hPGK-EGFP-HSVtk)
group was 90.12%. The apoptotic level was somewhat lower,
at 53.2%, in the cells infected individually with the vectors
carrying the lens epithelial cell specific promoter (LTKCRE),
while that of the negative control vector Lenti-IRES-EGFP
was 0.96%. For the RPECs, the percentages of apoptosis in
cells infected with different vectors were 10.12% (PGFPTK
and LTKCRE), 89.68% (Lenti-hPGK-EGFP-HSVtk), 8.62%
(LTKCRE), and 0.75% (Lenti-IRES-EGFP).
The  levels  of  apoptosis  in  HLECs  infected  with  the
enhanced  specific  lentiviral  vector  combination  were
obviously higher than those in the LTKCRE-infected groups,
and a specificity for HLECs over RPECs was also shown.
Cytotoxicity  of  the  HSV-tk/GCVsystem:  To  determine  the
effect of GCV on HLECs, the drug was added at increasing
concentrations (from 0 to 50 μg/ml) to four groups of cells
[infected  with  Lenti-hPGK-EGFP-HSVtk,  LTKCRE,  the
enhanced  specific  lentiviral  vector  combination  (PGFPTK
and  LTKCRE),  and  Lenti-IRES-EGFP],  which  were  then
incubated for 24 or 96 h. At each time point, the cytotoxicities
of the cells were assayed in triplicate for each concentration
using the Cell Counting Kit-8 (CCK-8).
The cell cytotoxicity gradually became more obvious
with increasing GCV concentrations (Figure 5). The results
indicated a dose-dependent effect on survival of the infected
HLECs treated with GCV. At a concentration of 20 µg/ml
after 96 h, there was no significant difference (p>0.05) in the
cell viability between the enhanced specific lentiviral vector
combination  and  the  Lenti-hPGK-EGFP-HSVtk  group.
However,  the  cell  viability  with  the  enhanced  specific
Figure 2. LEP503 promoter specifically,
but relative weakly, induced expression
of  EGFP  in  HLECs.  The  hPGK
promoter  and  LEP503  promoter-
induced  EGFP  expression  in  HLECs
was  detected  by  fluorescence
microscopy (A, B) and FACS (C, D).
RT–PCR analysis of EGFP expression
showed that PGFPTK can be expressed
well in HLECs and RPECs. However,
LGFPTK was specifically expressed in
HLECs and not in RPECs (E).
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(p<0.05)  than  that  of  LTKCRE-infected  cells.  The  cell
viability  of  the  enhanced  specific  lentiviral  vector
combination at 24 h was significantly higher (p<0.05) than
that at 96 h.
DISCUSSION
Clinically,  PCO  is  treated  by  Nd:YAG  capsulotomy  or
secondary  capsulotomy,  which  carries  a  risk  of  sight-
threatening complications such as cystoid macular edema,
retinal detachment, and increased intraocular pressure [3,4].
With the development of molecular biology, gene therapy for
PCO in vitro has made further advances. Several studies have
experimentally  demonstrated  the  cytotoxic  effects  of  the
HSV-tk/GCV system on lens epithelial cells and showed that
it effectively inhibits the proliferation of lens epithelial cells
in  vitro  [11,13,19,25,26].  However,  further  application  of
HSV-tk gene therapy for PCO treatment in vivo is dependent
on eliminating the toxic side effects on the cells surrounding
the lens epithelial cells. The use of the lens-specific promoter
LEP503 may be a desirable strategy for targeted gene therapy
for PCO. To increase the low expression activity of this tissue-
specific promoter [27], we used the Cre/loxP system involving
double lentivirus vectors in the present in vitro study.
In comparing HLECs infected by various vectors, no
EGFP-positive cells could be seen in the regulatory vector
LTKCRE-infected group, and very few were infected by the
enhanced specific lentiviral vector combination expressed-
EGFP; however, almost all of the HLECs in the targeted
vector  PGFPTK  group  expressed  EGFP,  as  observed  by
fluorescent  microscopy.  Western  blot  analysis  confirmed
these  EGFP  expressions.  For  HSV-tk,  there  was  weak
expression  in  the  HLECs  infected  by  the  targeted  vector
PGFPTK,  while  those  infected  by  the  regulatory  vector
Figure 3. The enhanced specific lentiviral vector combination induces high HSVtk protein expression in HLECs. After transfection with
LTKCRE, PGFPTK, and the enhanced specific lentiviral vector combination, the HLECs (A-C) and RPECs (D-F) were observed under a
fluorescence microscope and FACS at 72 h. Cells infected with LTKCRE did not express EGFP (A, D). The transduction efficiency of PGFPTK
measured by FACS was 97.43% and 92.15% in HLECs and RPECs, respectively (B, E). Meanwhile the transduction efficiency of the enhanced
specific lentiviral vector combination in HLECs and RPECs was 6.31% and 86.46%, respectively. Cre, EGFP, and HSV-tk protein expressions
in HLECs were analyzed by western blot for cells infected by different lentiviral vectors (G).
Molecular Vision 2011; 17:291-299 <http://www.molvis.org/molvis/v17/a35> © 2011 Molecular Vision
296LTKCRE showed stronger expression of HSV-tk. Finally, the
strongest  expression  of  HSV-tk  was  observed  in  HLECs
infected  by  the  enhanced  specific  lentiviral  vector
combination. Cre was only expressed in the HLECs infected
by the regulatory vector LTKCRE and the enhanced specific
lentiviral vector combination. These data demonstrated that
the use of the constructed double lentiviral vector combination
was successful in terms of the high level of the promoter
expression. However, there was weak expression of the HSV-
tk protein in HLECs infected by the targeted vector PGFPTK,
suggesting that the efficacy of the functional polyA sequence
needs further improvement.
This expression of HSV-tk in HLECs resulted in marked
specific enhancement of cytotoxicity after exposure to GCV.
Similar dose-dependent cytotoxic effects of GCV on infected
HLECs, as well as in other virus-mediated systems, have been
previously observed [11,20]. In our previous experiments, we
found that 20 to 25 μg/ml of GCV was the best range of
concentrations of GCV for inhibiting HSV-tk–positive cells
without cytotoxicity to normal cells [20]. We evaluated the
inhibitory  effect  of  the  HSV-tk/GCV  system  on  HLECs
through  analysis  of  apoptosis  and  viability  using  CCK-8.
After treatment of the cells with GCV at a concentration of
20  µg/ml  for  96  h,  the  apoptosis  rate  detected  by  flow
cytometry in the HLECs transduced by the enhanced specific
lentiviral  vector  combination  was  high,  at  87.23%.
Additionally,  the  cell  viability  of  the  enhanced  specific
lentiviral vector combination at 96 h was significantly lower
than that at 24 h, which indicated that apoptotic cells increased
with prolonged incubation time due to an in vitro bystander
effect of HSV-tk–expressing cells [20].
The double lentiviral vectors combination of the HSV-tk/
GCV system effectively inhibited the proliferation of HLECs
in our study. To verify our observations, electron microscopy
and EGFP detection were also applied, which showed that the
cytotoxic mechanism of the HSV-tk/GCV system includes
apoptosis and necrosis of infected cells. The fact that the
apoptosis rate was relatively high at 87.23% but not 100% is
Figure 4. Apoptosis profiles of HLECs at 96 h after infection by different vectors and treated with GCV at 20 µg/ml. Electron microscopy
showing subcellular structures of infected HLECs. The Lenti-IRES-EGFP infected cell nuclei were intact (A; magnification, 4880×). The
enhanced specific lentiviral vector combination infected HLECs appeared as apoptotic bodies (B; magnification, 6550×). Necrosis (cell
swelling, rounded mitochondrion, some subcellular structures) was seen in the cytoplasm (C; magnification, 4880×). The percentages of
apoptotic HLECs and RPECs infected by vectors: Lenti-hPGK-EGFP-HSVtk=90.12% and 89.68%, respectively; LTKCRE=53.2% and
8.62%, respectively, the enhanced specific lentiviral vector combination=87.23% and 10.12%, respectively; Lenti-IRES-EGFP=0.96% and
0.75%, respectively.
Figure 5. The dose and time dependency
of the HSV-tk/GCV system to affect cell
viability  detected  using  CCK-8.
Different concentrations of GCV were
added to the HLECs infected by Lenti-
IRES-EGFP,  LTKCRE,  the  enhanced
specific lentiviral vector combination,
or Lenti-hPGK-EGFP-HSVtk for 24 h
(A) or 96 h (B). The cell viability of the
group treated with the enhanced specific
lentiviral  vector  combination  was
significantly suppressed compared with
that treated with LTKCRE.
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297perhaps  an  advantage.  That  is,  killing  all  residual  lens
epithelial cells may ultimately result in capsular defects since
growth and/or maintenance of the capsule requires living lens
cells, especially in children [28,29].
In addition to the high HSV-tk expression in the lens
epithelial cells, the specific HSV-tk expression is another
important index in the evaluation of the enhanced specific
lentiviral vector combination. After the RPECs were infected
with  LGFPTK,  RT–PCR  analysis  showed  there  was  no
detectable  EGFP  in  the  cells,  while  the  infection  of  the
targeted vector PGFPTK or the enhanced specific lentiviral
vector combination resulted in nearly the same high level of
EGFP positive cells in the two groups. These data indicated
that there was no HSV-tk and Cre expression in RPECs under
the  control  of  the  lens-specific  promoter  LEP503.  After
treatment of the cells with GCV (20 µg/ml), even for 96 h,
there was little apoptotic effect on RPECs infected by the
enhanced specific lentiviral vector combination. Therefore,
the  double  lentiviral  vectors  combination  as  constructed
would  have  restricted  expression  of  HSV-tk  in  HLECs,
thereby avoiding toxic effects to the surrounding normal cells.
In conclusion, the lentiviral vector combination using the
Cre/loxP system can improve the expression of the HSV-tk
gene  driven  by  the  lens-specific  promoter  LEP503.  At  a
concentration of 20 µg/ml, GCV was effective against the
proliferation of HLECs in vitro, but had little killing effect on
RPECs. In future experiments, we will verify the inhibitory
effects of this lentiviral vector combination on the lens capsule
or PCO models.
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